BioCentury
ARTICLE | Clinical News

Jazz planning NDA for narcolepsy therapy JZP-258

April 5, 2019 6:19 PM UTC

Jazz said JZP-258 met the primary endpoint in a Phase III trial to treat cataplexy and excessive daytime sleepiness in adults with narcolepsy. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will meet with FDA to discuss the data and plans for an NDA submission.

Among 134 evaluable patients in the double-blind, international trial, JZP-258 significantly decreased the weekly number of cataplexy attacks over the 2-week randomized-withdrawal period vs. placebo. JZP-258 also met the secondary endpoint of improving Epworth Sleepiness Scale (ESS) score vs. placebo...

BCIQ Company Profiles

Jazz Pharmaceuticals plc

BCIQ Target Profiles

GABA B receptor